Shield Therapeutics plc (STX.L) Stock Price, Valuation & Analysis

Also trades on London Stock Exchange · STX.L (GBp) Other OTC · SHIEF (USD)

Description

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

Market Cap & Enterprise Value

Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook

Loading outlook…

Loading forecast...

Signal Summary Loading…

Indicator	1D	1W	2W	3W	1M

Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.

Day Score & sub-scores

Statistical fingerprint & regime detail

Conditional historical analysis

Customize analysis (advanced)

From To

Indicative levels generated algorithmically. Not financial advice.

Risk Profile

Loading risk profile…

Price Chart

From To

Averages

Trend

Price

Levels

Draw

GBp6.25 +0.00 (+0.00%)

Loading historical data…

Volume Profile

From To

Loading…

Liquidity & share structure

Average Volume

2M

Beta

1.78

Float Shares

405.06M

Free Float %

37.9%

Rolling Volatility

Loading…

Drawdown

Loading…

Relative Strength

Loading…

Monthly Returns Heatmap

From To

Loading…

Annual Monthly Returns

Loading…

Daily Returns Distribution

From To

vs.

Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Compare

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF

Current price

6.25

Ratings Trend (MoM) 100% Bullish

Rating	2026-04	Change
Strong Buy	0	0
Buy	3	0
Hold	0	0
Sell	0	0
Strong Sell	0	0

Quality scores

Altman Z-Score

-4.63

Distress

Piotroski F-Score

4 / 9

Average

MOAT Score

0 / 10

No MOAT

Composite Rating

C

Overall Score

2 / 5

Medium

DCF Score

1 / 5

Low

ROE Score

5 / 5

High

ROA Score

1 / 5

Low

D/E Score

1 / 5

Low

P/E Score

1 / 5

Low

P/Book Score

1 / 5

Low

Operational MOAT

✗ Below peers

✓
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%

+101.5% ★ Q4'25: +306.5% (vs Q4'23)
✗
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%

+12.8% Q4'25: +65.3% (vs Q4'23)
✗
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%

-26.9% Q4'25: -45.9% (vs Q4'23)
✗
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%

-20.3% Q4'25: -15.2% (vs Q4'23)
✓
ROIC Drug Manufacturers - Specialty & Generic: +6.5%

— Q4'25: +64.6% (vs Q4'23)
✓
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%

-2.6% ★ Q4'25: +43.3% (vs Q4'23)
✗
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×

0.00× Q4'25: 0.00× (vs Q4'23)

Valuation Multiples From To

DCF Interactive Model (UFCF)

Projection years:

Market assumptions

WACC (%)

Terminal g (%)

▶ WACC components (optional)

Risk-free rate (%)

Market risk premium (%)

Ke (Cost of Equity) = Rf + β (2.53) × ERP

WACC = 100% × Ke + 0% × Kd (3.9%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions

Revenue growth (%)

EBIT margin (%)

CapEx / Revenue (%)

Tax rate (%)

—

Current price: 6.25

Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates

Metric	Dec 2020 actual	Dec 2021 actual	Dec 2022 actual	Dec 2023 actual	Dec 2024 actual	Dec 2025 actual	Dec 2026 3 Rev. Ana. 2 EPS Ana.	Dec 2027 2 Rev. Ana. 1 EPS Ana.	Dec 2028 2 Rev. Ana. 1 EPS Ana.	Dec 2029 1 Rev. Ana.
Revenue	10.39M est: 9.34M (+11.2%)	1.52M est: 1.51M (+0.5%)	5.50M est: 8.55M (-35.7%)	13.09M est: 21.47M (-39.1%)	25.18M est: 25.74M (-2.2%)	50.74M est: 37.11M (+36.7%)	57.47M 52.55M – 61.42M +54.8% YoY	80.97M 74.04M – 86.55M +40.9% YoY	97.72M 89.36M – 104.45M +20.7% YoY	128.32M 117.33M – 137.15M +31.3% YoY
EBITDA	820.0K est: -38.23M (+102.1%)	-17.69M est: -32.15M (+45.0%)	-46.07M est: -71.23M (+35.3%)	-30.29M est: -15.37M (-97.0%)	-16.58M est: -144.08M (+88.5%)	-10.30M est: -26.57M (+61.2%)	-41.14M -43.97M – -37.62M -54.8% YoY	-57.96M -61.95M – -53.00M -40.9% YoY	-69.96M -74.77M – -63.97M -20.7% YoY	-91.86M -98.18M – -84.00M -31.3% YoY
EBIT	-1.89M est: -53.35M (+96.5%)	-19.90M est: -44.86M (+55.6%)	-48.94M est: -99.39M (+50.8%)	-31.36M est: -16.68M (-88.0%)	-17.69M est: -201.04M (+91.2%)	-10.30M est: -28.83M (+64.3%)	-44.64M -47.71M – -40.82M -54.8% YoY	-62.90M -67.23M – -57.51M -40.9% YoY	-75.91M -81.14M – -69.41M -20.7% YoY	-99.68M -106.54M – -91.15M -31.3% YoY
Net Income	-2.63M est: -51.96M (+94.9%)	-19.34M est: -43.70M (+55.7%)	-40.44M est: -48.88M (+17.3%)	-33.29M est: -42.49M (+21.6%)	-21.27M est: -21.24M (-0.2%)	-18.03M est: -9.41M (-91.5%)	-1.35M -1.49M – -1.22M +85.6% YoY	9.29M 8.34M – 10.23M +786.0% YoY	11.28M 10.02M – 12.29M +21.4% YoY	— — – — -100.0% YoY
SGA	5.90M est: 42.24M (-86.0%)	20.02M est: 6.84M (+192.9%)	27.33M est: 38.69M (-29.4%)	36.89M est: 97.12M (-62.0%)	27.07M est: 116.41M (-76.7%)	31.11M est: 167.86M (-81.5%)	259.91M 237.66M – 277.80M +54.8% YoY	366.22M 334.87M – 391.43M +40.9% YoY	441.99M 404.15M – 472.42M +20.7% YoY	580.37M 530.69M – 620.32M +31.3% YoY
EPS	-0.02 est: 0.00 (-462.8%)	-0.09 est: -0.09 (-9.9%)	-0.17 est: -0.08 (-105.8%)	-0.04 est: -0.05 (+21.8%)	-0.02 est: -0.03 (+12.0%)	-0.02 est: -0.01 (-88.6%)	0.00 0.00 – 0.00 +86.1% YoY	0.01 0.01 – 0.01 +786.0% YoY	0.01 0.01 – 0.01 +20.1% YoY	— — – — -100.0% YoY

Owner Earnings

Owner's Earnings (history) From To

Owner alignment

Owner's Earnings TTM

-24.26M

OE per share TTM

-0.03

Owner's Yield

-24.16%

Maintenance CapEx ratio

—

Maint CapEx / Avg PPE

1.5%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance

Institutional holders

—

Total invested

—

Insider transactions (90d)

0

Beneficial owners (>5%)

0

Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives

EBIT / Employee

-168.8K

Shares Outstanding

1.07B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

No SEC filings available for this company yet.

Executive team

Name	Title	Compensation	Gender
Anders Lundstrom	CEO & Executive Director	115.2K	male
Christian Schweiger	Co-Founder & Non Executive Director	38.1K	—
Carol Akinola	Head of Pharmacovigilance & Medical Information	—	female
Kate Armanetti	Senior Director of People & Culture	—	—
Lucy Kate Huntington-Bailey	General Counsel, Chief Compliance Officer & Company Secretary	—	female
Santosh Shanbhag	Chief Financial Officer	—	male
Suzanne Wood	Group HR Director	—	female
Andrew Hurley	Chief Commercial Officer	—	male

ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers

Peer comparison — filtered group (TTM)

Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Shield Therapeutics plc (STX.L)

Revenue flow

Revenue by geography

Revenue by segment

Revenue composition

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Owner Earnings

Ownership Overview

Institutional Activity (13F)

ETF Ownership

Insider Activity

Executive team

Executive compensation

Proxy statements

Recent SEC filings

Executive team

Community Opinion for STX.L

Short-term intention

Target Price Distribution

Dividend history

Earnings history

Earnings reports

Stock splits

Shield Therapeutics plc (STX.L)

Revenue flow

Revenue by geography

Revenue by segment

Revenue composition

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Owner Earnings

Ownership Overview

Institutional Activity (13F)

ETF Ownership

Insider Activity

Executive team

Executive compensation

Proxy statements

Recent SEC filings

Executive team

Community Opinion for STX.L

Short-term intention

Target Price Distribution

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies